Kjersti Støen Grotmol1, Hanne C Lie2,3,4, Jon Håvard Loge1,3,5, Nina Aass6,7, Dagny Faksvåg Haugen8,9, Patrick C Stone10, Stein Kaasa5,6,7, Marianne Jensen Hjermstad1,5. 1. Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital. 2. Department of Paediatric Medicine, Oslo University Hospital, Oslo, Norway. 3. Department of Behavioural Sciences in Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 4. National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway. 5. European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology and St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. 6. Faculty of Medicine, University of Oslo, Oslo, Norway. 7. Department of Oncology, Oslo University Hospital, Oslo, Norway. 8. Regional Centre of Excellence for Palliative Care, Western Norway, Haukeland University Hospital, Bergen, Norway. 9. Department of Clinical Medicine K1, University of Bergen, Bergen, Norway. 10. Marie Curie Palliative Care Research Department, University College London, UK.
Abstract
OBJECTIVE: Clinical observations indicate that patients with advanced cancer and depression report higher symptom burden than nondepressed patients. This is rarely examined empirically. Study aim was to investigate the association between self-reported depression disorder (DD) and symptoms in patients with advanced cancer controlled for prognostic factors. METHOD: The sample included 935 patients, mean age 62, 52% males, from an international multicentre observational study (European Palliative Care Research Collaborative - Computerised Symptom Assessment and Classification of Pain, Depression and Physical Function). DD was assessed by the Patient Health Questionnaire-9 and scored with Diagnostic and Statistical Manual of Mental Disorder-5 algorithm for major depressive disorder, excluding somatic symptoms. Symptom burden was assessed by summing scores on somatic Edmonton Symptom Assessment Scale (ESAS) symptoms, excluding depression, anxiety, and well-being. Item-by-item scores and symptom burden of those with and without DD were compared using nonparametric Mann-Whitney U tests. The relative importance of sociodemographic, medical, and prognostic factors and DD in predicting symptom burden was assessed by hierarchical, multiple regression analyses. RESULT: Patients with DD reported significantly higher scores on ESAS items and a twofold higher symptom burden compared with those without. Factors associated with higher symptom burden were as follows. Diagnosis: lung (β = 0.15, p < 0.001) or breast cancer (β = 0.08, p < 0.05); poorer prognosis: high C-reactive protein (β = 0.08, p < 0.05), lower Karnofsky Performance Status (β = -0.14, p < 0.001), and greater weight loss (β = -0.15, p < 0.001); taking opioids (β = 0.11, p < 0.01); and having DD (β = 0.23, p < 0.001). The full model explained 18% of the variance in symptom burden. DD explained 4.4% over and above that explained by all the other variables. SIGNIFICANCE OF RESULTS: Depression in patients with advanced cancer is associated with higher symptom burden. These results encourage improved routines for identifying and treating those suffering from depression.
OBJECTIVE: Clinical observations indicate that patients with advanced cancer and depression report higher symptom burden than nondepressed patients. This is rarely examined empirically. Study aim was to investigate the association between self-reported depression disorder (DD) and symptoms in patients with advanced cancer controlled for prognostic factors. METHOD: The sample included 935 patients, mean age 62, 52% males, from an international multicentre observational study (European Palliative Care Research Collaborative - Computerised Symptom Assessment and Classification of Pain, Depression and Physical Function). DD was assessed by the Patient Health Questionnaire-9 and scored with Diagnostic and Statistical Manual of Mental Disorder-5 algorithm for major depressive disorder, excluding somatic symptoms. Symptom burden was assessed by summing scores on somatic Edmonton Symptom Assessment Scale (ESAS) symptoms, excluding depression, anxiety, and well-being. Item-by-item scores and symptom burden of those with and without DD were compared using nonparametric Mann-Whitney U tests. The relative importance of sociodemographic, medical, and prognostic factors and DD in predicting symptom burden was assessed by hierarchical, multiple regression analyses. RESULT: Patients with DD reported significantly higher scores on ESAS items and a twofold higher symptom burden compared with those without. Factors associated with higher symptom burden were as follows. Diagnosis: lung (β = 0.15, p < 0.001) or breast cancer (β = 0.08, p < 0.05); poorer prognosis: high C-reactive protein (β = 0.08, p < 0.05), lower Karnofsky Performance Status (β = -0.14, p < 0.001), and greater weight loss (β = -0.15, p < 0.001); taking opioids (β = 0.11, p < 0.01); and having DD (β = 0.23, p < 0.001). The full model explained 18% of the variance in symptom burden. DD explained 4.4% over and above that explained by all the other variables. SIGNIFICANCE OF RESULTS: Depression in patients with advanced cancer is associated with higher symptom burden. These results encourage improved routines for identifying and treating those suffering from depression.
Authors: Teresa Thomas; Andrew Althouse; Lauren Sigler; Robert Arnold; Edward Chu; Douglas B White; Margaret Rosenzweig; Kenneth Smith; Thomas J Smith; Yael Schenker Journal: Psychooncology Date: 2021-03-08 Impact factor: 3.955
Authors: Eida M Castro-Figueroa; Normarie Torres-Blasco; Milagros C Rosal; Julio C Jiménez; Wallesca P Castro-Rodríguez; Marilis González-Lorenzo; Héctor Vélez-Cortés; Alia Toro-Bahamonde; Rosario Costas-Muñiz; Guillermo N Armaiz-Peña; Heather Jim Journal: Nurs Rep Date: 2021-06-09
Authors: Emma J Chapman; Simon Pini; Zoe Edwards; Yousuf Elmokhallalati; Fliss E M Murtagh; Michael I Bennett Journal: BMC Palliat Care Date: 2022-02-04 Impact factor: 3.234